All Articles

Preliminary results of the FOENIX-CCA2 study show that futibatinib may be effective and well-tolerated in patients with locally advanced or metastatic unresectable intrahepatic CCA harboring FGFR2 gene fusions following failure of prior lines of chemotherapy.

Results of the global phase 2 FOENIX-CCA2 trial support the efficacy and safety of futibatinib treatment in patients with locally advanced or metastatic unresectable intrahepatic CCA and FGFR2 fusions or rearrangements, and indicate that futibatinib does not adversely affect patients’ quality of life.

Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.

As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!

Results of a phase 2 study indicate that mFOLFIRI was not superior to mFOLFOX in the second-line treatment of patients with biliary tract cancer.

Results of the PK/PD analysis of the ClarIDHy study showed that the study dose of the IDH1 inhibitor ivosidenib resulted in good exposure and inhibition of oncometabolite D-2-HG.

Results of the retrospective analysis of phase 2 study of the FGFR1-3 selective tyrosine kinase inhibitor infigratinib indicate that efficacy outcomes in patients with CCA and FGFR2 fusions were better with third- or later-line infigratinib therapy compared with standard second-line chemotherapy.

Retrospective analysis data indicate that adjuvant chemoradiotherapy was associated with improved survival compared with chemotherapy alone in patients with extrahepatic CCA.

Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.

Phase 2 study results suggest that the addition of nivolumab and ipilimumab to chemotherapy as first-line therapy did not provide additional PFS benefit compared to standard-of-care chemotherapy in patients with advanced biliary tract cancer.